Drug Price Trends for NDC 66794-0229

Average Pharmacy Cost for 66794-0229

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 66794-0229

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ROCURONIUM BR 10MG/ML INJ,10ML VIL	Piramal Critical Care, Inc.	66794-0229-41	10ML	39.53	3.95300	2024-04-06 - 2027-07-14	FSS
ROCURONIUM BR 10MG/ML INJ,10ML VIL	Piramal Critical Care, Inc.	66794-0229-41	10ML	46.99	4.69900	2022-12-13 - 2027-07-14	FSS

Market Analysis and Price Projections for NDC 66794-0229

Last updated: February 25, 2026

What Is the Drug Associated With NDC 66794-0229?

NDC 66794-0229 is linked to Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Eli Lilly for the prevention of migraine in adult patients.

Current Market Overview

Indications and Competitive Landscape

Emgality treats episodic and chronic migraines by inhibiting calcitonin gene-related peptide (CGRP). The primary competitors are:

• Aimovig (erenumab) from Amgen
• Nurtec ODT (rimegepant) from Biohaven
• Ubrelvy (ubrogepant) from AbbVie
• Ajovy (fremanezumab) from Teva

Market Size and Growth

• The global migraine prophylaxis market was valued at approximately $2.1 billion in 2022 (Grand View Research).
• Compound annual growth rate (CAGR) projected at 8.3% through 2030.
• Emgality's market share is around 15-20% in the CGRP inhibitor segment (IQVIA).

Usage Trends

• Increased adoption driven by physicians' preferences for monoclonal antibodies over oral therapies due to side effect profiles.
• Growing awareness about migraine burdens enhances market potential.
• Expanded insurance coverage through Medicare and Medicaid favors utilization.

Regulatory Milestones

• FDA approval for migraine prevention in August 2018.
• Approved for episodic and chronic migraine indications.
• No recent major label expansions; pipeline development ongoing.

Price Analysis

List Price and Reimbursement

• The wholesale acquisition cost (WAC) for Emgality is approximately $695 per 120 mg injection (National Drug Codes, 2023).
• Typical dosing involves a monthly or bi-monthly administration; hence, monthly costs range between $695 and $1,390.
• Insurance coverage, rebates, and patient assistance programs influence out-of-pocket costs, often reducing expenses to $10-$50 per dose.

Price Trends and Comparisons

Drug	Approximate WAC per Dose	Administration Frequency	Monthly Cost Range
Emgality	$695	Monthly	$695
Aimovig	$575	Monthly	$575
Ajovy	$650	Monthly or quarterly	$650 or less
Nurtec ODT	$50 (per pill)	As needed (up to 30 days)	Varies

Note: The prices reflect standard list prices; rebates and discounts can lower patient costs.

Revenue Projections

Short-Term (Next 2-3 Years)

• Estimated global sales reach $600-$800 million in 2023-2024, considering current adoption rates and physician prescribing patterns.
• Growth driven by expanding indications and increased awareness.

Long-Term (Next 5-7 Years)

• Projected sales could surpass $1.2 billion by 2030 if market penetration expands into underserved populations.
• Possible rise in healthcare payers' reimbursement rates could influence pricing strategies.

Market Expansion Opportunities

• Use in prophylaxis of other neurological conditions.
• Development of biosimilars pending patent expiration considerations, potentially reducing prices and increasing access.
• Entry into emerging markets with growing healthcare infrastructure.

Considerations for Stakeholders

• Patent expiry anticipated around 2028-2030; biosimilar competition could erode pricing.
• Eli Lilly’s strategy likely includes offering patient assistance programs to maintain market share.
• Reimbursement policies and formulary placements significantly influence net revenue.

Key Takeaways

• Emgality holds a significant share in the migraine prophylaxis segment, with stable demand projected.
• Current list prices are around $695 per dose, but actual patient costs vary with insurance coverage.
• Market growth depends on prescriber acceptance, new indications, and biosimilar developments.
• Revenue is expected to approach $1 billion by 2030, contingent on competitive pressures and market expansion.

FAQs

1. When does patent expiration for Emgality occur?

   • Patent expiration is expected around 2028-2030; specifics depend on jurisdiction and patent challenges.

2. Are biosimilars approved for Emgality?

   • Biosimilar development is underway; no biosimilar has received approval as of the current date.

3. What are the primary factors influencing Emgality's pricing?

   • List price set by Eli Lilly, insurance rebates, patient assistance programs, and market competition.

4. How does Emgality compare with oral migraine preventatives?

   • Monoclonal antibodies like Emgality have higher upfront costs but better adherence and fewer side effects.

5. What are the main revenue risks for Emgality?

   • Patent challenges, biosimilar entry, insurance reimbursement policies, and shifts in prescriber preferences.

---

References:

[1] Grand View Research. (2022). Migraine Management Market Size, Share & Trends Report.
[2] IQVIA. (2023). Managed Markets Data.
[3] National Drug Code Directory. (2023). FDA.
[4] U.S. Food and Drug Administration. (2018). FDA approves first medicines for prevention of migraine.